semaglutide hospitalizations FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable products GLP-1 receptor agonists, including semaglutide

On April 1, 2026, the FDA issued a significant policy clarification targeting the most common remaining workaround: compounders and telehealth providers had been adding a secondary ingredient most commonly vitamin B12 to their semaglutide formulations and marketing them as distinct, patient-specific products not subject to the "essentially a copy" prohibition

Czimmerer et al., 2023) The BPC-157 + TB-500 blend is a research compound scientists study for its potential to help the body recover and repair itself at the cellular level

Only 18% of people felt they got all the answers to questions about their care from healthcare professionals

Always place used needles, syringes and related supplies in an FDA-cleared sharps container or another designated disposal container immediately after use